Also known as Erleada.
Quarterly sales topped $25.3B; adjusted net earnings and EPS rose, free cash flow improved, and full-year revenue guidance was raised above $100B for the first time.
Perioperative apalutamide + ADT (6 months pre/post-surgery) raised pCR/MRD to 8.9% vs 1%, delayed need for further therapy >6 vs 3.5 years, met dual primary endpoints; safety profile as expected.
Real-world study shows ERLEADA® offers significant survival benefits for mCSPC patients without docetaxel, supporting its use as a standard treatment.
